ilmscore | Indegene IPO: 10 min summary | CA Rachana Ranade

Indegene IPO: 10 min summary | CA Rachana Ranade

Published: 2024-05-07
Status: Available | Analyzed

Predictions from this Video

Total: 8
Correct: 0
Incorrect: 0
Pending: 8
Unrated: 0
Prediction
Topic
Status
The life science industry market size is projected to grow from USD 1.8 trillion in 2020-2023 to USD 2.1 trillion by 2026.
"we have certain uh data points here as to what was the industry size in 2020-23 which was around $11.8 US trillion dollar this is expected to grow uh to by 2026 to 163.5 trillion uh sorry so from US 1.8 trillion to US 2.1 trillion"
Life Science Industry Market Size
Pending
Indegene's revenue has grown at a CAGR of approximately 54% between financial years 21-23.
"if you see a revenue from operations has gone straight up from 966 crores to 1,664 crores to 2,036 crores, I'm talking about financial years 21-22 and 23 and this CAGR comes up to around 54% so revenue has grown at almost 54% CAGR"
Indegene Revenue Growth
Pending
Indegene's EBITDA margin has increased from 15.97% to 19.69% (excluding a COVID-influenced 27% figure).
"EBITDA margin has the the margin trend if you can see it was at 27% dropped to 15.97% again up to 19%. The management has very clearly mentioned that this 27% was on a higher side because of the covid year so let's ignore that so we can just say that from 15.97% it has gone up to 19.69%"
Indegene EBITDA Margin
Pending
Indegene's PAT has shown an increasing trajectory, with a CAGR of approximately 19%.
"and if I'm talking about PAT, same old story this was exceptional here they have gone from 99.78% to 11.54% okay so all in all this is also in an increasing trajectory. So as I mentioned revenue CAGR is at 54% EBITDA, CAGR is at 31% roughly and PAT, CAGR is somewhere around 19%"
Indegene PAT Growth
Pending
Approximately 71% of Indegene's revenue is generated from sales and marketing activities, specifically Enterprise Commercial Solutions (59%) and Omni Channel Activation (12%).
"every 100 rupee earn for that the split 59% is Enterprise Commercial Solutions, 12% is Omni Channel Activation so if I just add these two up 59% and 12% so almost 71% is generated from that sales and marketing remember that digital marketing and physical sales and online all these 71% is a bigger chunk right."
Indegene Revenue Segmentation
Pending
Indegene operates in a market with no directly comparable listed peers globally, giving it a potential competitive advantage.
"comparison there are no listed companies in India and globally that are of the comparable size from the same industry with similar business model as that of the company very clearly they have mentioned so that is why in our blog also we have written no listed peers in India or globally, Can I say this is a big very big advantage for the company as well? Absolutely Yes"
Indegene Competitive Landscape
Pending
90% of the spending in the life science operations industry occurs in North America (65%) and Europe (25%).
"you can see this whole industry only where does the major spend happen for life science operations where does the spend happen 65% North America, 25% Europe. 90% life sign spend is in North America and Europe"
Life Science Industry Spend Concentration
Pending
Indegene's top 10 clients account for approximately 67% of its total revenue.
"top 10 customers contribute to almost 67% of the revenue."
Indegene Client Concentration
Pending